Close menu




August 3rd, 2022 | 10:50 CEST

Varta at EUR 64 or EUR 102? Will BioNTech and Kleos Space make the breakout?

  • Space
  • Biotechnology
  • Electromobility
Photo credits: pixabay.com

The stock market environment is currently friendly, and technology stocks, in particular, are in a recovery rally. Investors are driven by the hope that inflation will weaken and that an end to the interest rate increase cycle of the US Federal Reserve will at least become foreseeable. If this were the case, we would not be in a bear market rally, but at the beginning of a new bull market. But not all stocks have been able to benefit from the good mood in recent weeks. Rightly so? In the case of Varta, the answer is yes - the Company shocked shareholders with a profit warning on Saturday. However, the price targets of analysts diverge significantly. The BioNTech share is unusually quiet. There is positive news from the Company itself and its partner Pfizer. With the quarterly figures next week, an attempt to break out of the sideways trend could take place. Kleos Space is also currently making this attempt. Investors are positioning themselves with the high-tech company in preparation for the next milestone.

time to read: 4 minutes | Author: Fabian Lorenz
ISIN: VARTA AG O.N. | DE000A0TGJ55 , BIONTECH SE SPON. ADRS 1 | US09075V1026 , KLEOS SPACE CDI/1/1 | AU0000015588

Table of contents:


    David Elsley, CEO, Cardiol Therapeutics Inc.
    "[...] As a company dedicated to developing treatments for rare heart diseases, we see this as an opportune moment to contribute to the fight against heart disease and make meaningful strides in improving heart health worldwide. [...]" David Elsley, CEO, Cardiol Therapeutics Inc.

    Full interview

     

    Kleos Space: Investors position themselves for the next milestone

    Security and surveillance have been growth markets not just since the Russian war of aggression on Ukraine. Surveillance from space is probably one of the most exciting topics. And that brings us to Kleos Space. Founded in Australia, the Luxembourg-based high-tech company develops satellites to help fight global environmental, security and economic problems by collecting and analyzing radio frequency signals from space for geolocation. The high-quality data sets are sold to government organizations and commercial companies as 'Data-as-a-Service' on a subscription model. Kleos currently has a global pipeline of more than 260 partners, including ministries of defense, national security agencies, coast guards, sanctions agencies and data aggregators. Most recently, a partnership with the US Navy was announced.

    "Data is the foundation for all decisions. Our recent agreement with the US Navy is an excellent example of a government user engaging early with unique data sets like ours to quickly develop innovative solutions to military challenges that enable faster decision making," said Kleos Space CEO Andy Bowyer as part of the Q2 update release. The Company also published its goal of achieving positive adjusted EBITDA as early as the second half of 2022. At the same time, the Company is still in the build-out phase of its satellite network. So far, 3 of the planned 20 satellite clusters have been launched. Cluster number 4 is scheduled to be launched into space in October as part of a rocket launch by Elon Musk's SpaceX. Funding for further missions has also been secured through a USD 10 million corporate action. Accordingly, the share has reacted positively in recent weeks, rising from EUR 0.25 to EUR 0.33. However, there is still room for improvement up to the 52-week high of EUR 0.60. Against the background of the exciting future prospects and the emerging profitability, the current market capitalization of AUD 88 million does not seem too high.

    Varta: EUR 64 or EUR 102?

    The expansion into electromobility electrifies Varta shareholders. But the Company is making slower progress on this path than expected. It has still not reported a major cooperation, and then last Saturday also lowered its forecasts for the current year. Accordingly, the Swabian battery manufacturer expects sales of between EUR 880 and 920 million (previously at least EUR 950 million). EBITDA is expected to be between EUR 200 and 225 million. Previously, EUR 260 to 280 million had been targeted. In a first reaction, Warburg Research downgraded the Varta share from "Buy" to "Sell". The price target was reduced from EUR 95 to EUR 65.50. Due to the high investments in the development of the production of V4Drive cells for e-cars, there is a need for capital. Hauck Aufhäuser also significantly reduced the price target from EUR 84 to EUR 64. The recommendation was also previously "Sell". It said that market conditions are currently deteriorating further and therefore reduced estimates for 2022 and the coming years.

    Goldman Sachs is less disappointed with Varta. The original forecast was ambitious; therefore, the adjustment did not come as a complete surprise. Although the share is burdened for the time being, the analysts continue to recommend buying. The price target was left at EUR 102. According to the experts from researchanalyst.com, Varta has now disappointed for the third time in a row. They demand that the Varta management respond more to the market's expectations and explain the status quo in the field of e-mobility in more detail.

    BioNTech: Dividend yield is now at an attractive level

    It has been quiet around the BioNTech share in recent weeks. This could soon be over and the share may even break out to the upside. It was recently announced that BioNTech, together with US partner Pfizer, have started the Phase 2 study of the efficacy and safety of a next-generation vaccine candidate to protect against COVID-19. The vaccine will initially be tested on approximately 200 individuals in the United States. The goal is to achieve a longer-lasting and broader immune response.

    Then partner Pfizer also beat analysts' expectations with its quarterly figures. The Company generated nearly USD 9 billion in revenue from the COVID-19 vaccine alone, which was more than expected. For the full year 2022, Pfizer expects revenues of USD 27.7 billion from vaccine sales. As a result, BioNTech is also likely to report strong quarterly results next week. These are to be published on August 8. Analysts should then also have their say again. At the beginning of July, Deutsche Bank published an update on BioNTech shares with a hold rating and a price target of USD 180. The share is currently trading at just over USD 160.


    Share prices are currently developing positively across the board. BioNTech has not benefited from this so far, but this could change next week. Kleos Space shares should also continue to increase as the launch of the fourth satellite cluster approaches. Varta has lost further trust and must finally publish convincing news on its expansion in the field of electromobility.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.


    Der Autor

    Fabian Lorenz

    For more than twenty years, the Cologne native has been intensively involved with the stock market, both professionally and privately. He is particularly passionate about national and international small and micro caps.

    About the author



    Related comments:

    Commented by Fabian Lorenz on February 21st, 2024 | 07:00 CET

    Top news: BYD, Bayer and Globex Mining

    • Mining
    • Gold
    • Commodities
    • Electromobility
    • chemicals

    Bayer shocked investors yesterday with the announcement of its dividend cut, which shouldn't have been much of a surprise. The Company is burdened with high debt, endless legal fines, and an empty pharmaceutical pipeline. In an initial reaction, analysts have lowered the share price target. BYD, on the other hand, is doing well operationally. Only the share price is not picking up. Will a share buyback turn the share price around? For those who want to profit from the commodity boom with reduced risk, then Globex Mining's stock is attractive. The news flow is strong, and those who act quickly can still register and follow the live presentation of the mining incubator at the 10th International Investment Forum, IIF, today.

    Read

    Commented by Armin Schulz on February 20th, 2024 | 07:45 CET

    ThyssenKrupp Nucera, dynaCERT, Plug Power - Hydrogen Stocks: Buy or Wait?

    • Hydrogen
    • Electromobility
    • greenhydrogen

    In light of global efforts to reduce CO2 emissions, hydrogen is coming into focus as a promising alternative in the transportation sector. The quick refueling times and greater ranges of hydrogen are particularly enticing, potentially solving the challenges of electromobility. Fleet operators must also become active, especially in response to the savings demanded by the government. Despite the clear potential for more sustainable mobility, hydrogen companies currently find themselves in a challenging situation on the stock markets, plagued by market uncertainties and the challenges of a nascent technology. Today, we look at three companies whose business is based on hydrogen.

    Read

    Commented by André Will-Laudien on February 20th, 2024 | 07:30 CET

    Takeover fever in the biotech sector! Will MorphoSys now be followed by Defence Therapeutics, Evotec and Bayer?

    • Biotechnology
    • Pharma
    • Innovations

    It has happened: Novartis is bidding for MorphoSys. Once again, a long-lasting and persistent rumour mill eventually confirms itself. Those who remained loyal to MorphoSys despite heavy selling last fall have now made a profit of over 300%. If we turn the analytical magnifying glass on the sector, we can see that the speculative biotech stock market segment has started to move again since the challenging year 2023. Hopes of falling interest rates in the near future, along with several other M&A hopes, have led to steady inflows into listed bio-ETFs, resulting in fund managers having recently adjusted their weightings upwards. We analyze which stocks are currently making the loudest noise.

    Read